Douglas K. Price, Ph.D.
Dr. Price’s research focuses on the molecular biology of prostate cancer with emphasis on the goals of (1) understanding the biology of prostate cancer progression and the transition from androgen-dependent disease to castrate resistant prostate cancer (CRPC), (2) exploring the impact of genetic polymorphisms in androgen regulatory pathways on clinical outcomes, and (3) developing targeted therapies against CRPC with emphasis on the design and development of small molecule inhibitors of angiogenesis, transporters and hypoxia factors. Dr. Price also acts as the laboratory biorepository curator, overseeing the banking and storage of genetic materials from patients with prostate cancer.
1) molecular biology, 2) genetics, 3) prostate cancer, 4) angiogenesis
Center for Cancer Research
National Cancer Institute
Building 10 - Magnuson CC, Room 5A01
Bethesda, MD 20892
Dr. Price is currently investigating the regulation of androgens. Androgens are the primary driver in the etiology of prostate cancer. All genes and gene products involved with the synthesis and regulation of androgens contribute to an individual's risk of developing prostate cancer. Single polymorphic genes do not exclusively explain a complex, late-onset, chronic disease such as prostate cancer, but identification of genes that increase risk will contribute to a larger-scale multigenic risk assessment. To this end, the laboratory is interested in understanding the associations between important androgen regulatory genes and prostate cancer risk, and elucidating the complex process of prostate cancer aggressiveness and progression. One example of Dr. Price’s work is the ongoing study of the SLCO1B3 gene that encodes the membrane transporter OATP1B3. Membrane transporters play active roles in drug disposition by transporting substrate drugs between organs and tissues, and we have shown that this gene is involved in testosterone transport into cells. The long-term goal of this project is to continue to characterize the role of OATP1B3 in prostate cancer and understand the molecular mechanisms controlling its expression. This is vital for future drug discovery efforts and the potential inhibition of this important transporter. Dr. Price is now involved with developing the infrastructure that will allow a high-throughput assay to find candidate OATP1B3 inhibitors from the drug library at NCI's Molecular Targets Drug Development Program, and to develop this identified inhibitor.
Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial.Urology. 84: 127-31, 2014. [ Journal Article ]
Epidithiodiketopiperazines (ETPs) exhibit antiangiogenic and antitumor activity by disrupting the HIF-1alpha/p300 complex in a preclinical model of prostate cancer.Mol Cancer . 13: 91, 2014. [ Journal Article ]
Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.J Urol . 184: 2297-2302, 2010. [ Journal Article ]
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.BJU Int. 102: 617-21, 2008. [ Journal Article ]
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostate cancer.Clin Cancer Res. 14: 3312-8, 2008. [ Journal Article ]
Dr. Price received his B.S. degree in Microbiology from the University of Arkansas, and his Ph.D. in molecular and cell biology from the Pennsylvania State University. Upon completion of his degree, Dr. Price was awarded a Howard Hughes Medical Institute post-doctoral fellowship at the Emory University School of Medicine. Dr. Price next spent 6 years as the Director of Molecular Biology at the Carolinas Medical Center in Charlotte, North Carolina. In 2000, Dr. Price joined the NCI and has continued his work on the molecular biology of prostate cancer.